Cite

HARVARD Citation

    Zangardi, M. et al. (2019). Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?. Expert opinion on investigational drugs. pp. 107-112. [Online]. 
  
Back to record